Global Hemostasis Products Market

Hemostasis Products Market Size, Share, Growth Analysis, By Product(Topical Hemostasis Products, Infusible Hemostasis Products, Advanced Hemostasis Products), By Application(Trauma, Surgery, Hemophilia, Myocardial Infarction), By End-user(Hospitals, Clinics, and Others), By Region - Industry Forecast 2024-2031


Report ID: SQMIG35A2702 | Region: Global | Published Date: April, 2024
Pages: 219 | Tables: 91 | Figures: 76

Hemostasis Products Market News

  • In April 2024, Sysmex America, Inc., a leading diagnostic solutions company offering hematology, urinalysis, information systems and flow cytometry testing technology, announced its plan to sell hemostasis instruments and reagents to laboratories in the United States beginning in April, under the company's mutual OEM agreement with Siemens Healthineers. 
  • In November 2023, Ethicon, a Johnson & Johnson MedTech company, announced the approval of ETHIZIA™, an adjunctive hemostat solution which has been clinically proven to achieve sustained hemostasis in difficult to control bleeding situations. 
  • In March 2023, Werfen announced that it had successfully completed the acquisition of Immucor, Inc., after obtaining all necessary regulatory and antitrust approvals. The Transfusion and Transplant product lines complement Werfen's existing Hemostasis, Acute Care and Autoimmunity business lines, expanding its portfolio of Specialized Diagnostic solutions for hospitals and clinical laboratories.
$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Hemostasis Products Market size was valued at USD 1.60 billion in 2022 and is poised to grow from USD 1.69 billion in 2023 to USD 2.59 billion by 2031, growing at a CAGR of 5.5% in the forecast period (2024-2031).

In the enormously competitive hemostasis products marketplace, numerous organizations are vying for market percentage. These gamers are engaged in strategic projects which include product innovation, collaborations, and mergers and acquisitions to bolster their positions. The marketplace's competitiveness is driven through the consistent pursuit of novel technology and answers to cope with bleeding disorders and decorate surgical results. 'Johnson & Johnson (US)', 'Pfizer (US)', 'Baxter International (US)', 'Medtronic (US)', 'B. Braun Melsungen AG (Germany)', 'Becton, Dickinson, and Company (BD) (US)', 'Tricol Biomedical (US)', 'Hemostasis LLC (US)', 'CuraMedical BV (Netherlands)', 'Teleflex Incorporated (US)', 'CryoLife, Inc. (US)', 'Ethicon, Inc. (US)', 'Grifols, S.A. (Spain)', 'Terumo Corporation (Japan)', 'Integra LifeSciences Holdings Corporation (US)', 'HemCon Medical Technologies, Inc. (US)', 'Zimmer Biomet Holdings, Inc. (US)', 'Haemonetics Corporation (US)', 'CSL Behring LLC (Australia)', 'Olympus Corporation (Japan)'

Innovations such as the improvement of extra green and safer hemostasis products, along with hemostatic agents and gadgets, are substantially improving the remedy of bleeding issues and surgical procedures. These improvements improve patient consequences and pressure market increase.

Growing Emphasis on Minimally Invasive Hemostasis Techniques: Healthcare companies and sufferers alike are searching for much less invasive strategies to manage bleeding issues and surgical techniques. This trend is using the development of progressive hemostasis merchandise and techniques that reduce tissue damage, reduce restoration time, and enhance usual affected person results. Minimally invasive hemostasis methods are becoming increasingly popular due to their potential for greater patient comfort and shorter hospital stays, which align with the broader healthcare industry's focus on value-based care.

North America currently dominates the hemostasis products market. This dominance can be attributed to well-established healthcare infrastructure, a high prevalence of surgical procedures, and a growing elderly population.The region also benefits from significant research and development investments, driving innovation in hemostasis products.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Hemostasis Products Market

Report ID: SQMIG35A2702

$5,300
BUY NOW GET FREE SAMPLE